CURRICULUM VITAE
KARL E. ANDERSON, M.D. February 2, 2006
PRESENT POSITION AND ADDRESS:
April 1987-Present: Professor,
Departments of Preventive Medicine and Community Health (Division of Human
Nutrition), Internal Medicine (Division of Gastroenterology), and Pharmacology
and Toxicology
September 1990-Present: Director, Division of Human Nutrition
December 1993-Present: Associate Program Director, General Clinical Research
Center
September 1998-Present: Director, Clinical Research Education Office.
Office: Ewing Hall (3.102L), 700 Harborside Drive, The University of Texas Medical Branch, Galveston, Texas 77555-1109.
Telephone:
409-772-4661. FAX: 409-772-6287. Email: kanderso@utmb.edu.
BIOGRAPHICAL:
Born: May
16, 1940. Buffalo, New York
Citizenship: U.S.A.
Married: Mary
Patricia Wood (Patty), Galveston, TX,
2000
Children: Matthew
Dana, b. 1984; Gillian Carol, b. 1986; Jeffrey Karl, b. 1990
Residence: 4726
Caduceus Place, Galveston, TX 77551. Telephone, 409-744-5737
EDUCATION AND POSTGRADUATE TRAINING:
August 1958-June 1960 The College of Wooster, Wooster, Ohio
August 1960- June 1962 The Johns Hopkins University, Baltimore, Maryland
(B.A. Degree, 6/1962)
August 1960- June 1965 The Johns Hopkins University School of Medicine (M.D.
Degree, 6/8/1965)
July 1965- June 1967 Internship
and Residency, Internal Medicine, Vanderbilt University Hospital, Nashville,
Tennessee.
July 1967- June 1968 Residency, Internal Medicine, The New York
Hospital-Cornell Medical Center, New York, N. Y.
July 1968- June 1970 Fellowship
in Gastroenterology, The New York Hospital-Cornell Medical Center, New York, N.
Y.
PROFESSIONAL AND TEACHING EXPERIENCE:
1970-1971 Instructor
in Medicine, Cornell University Medical College, New York, N.Y.
1968-1971 Guest
Investigator, The Rockefeller University, New York, N. Y.
1971-1973 Clinical
Investigation Department, U.S. Naval Medical Research Unit No.2, Taipei, Taiwan
1973-1979 Assistant
Professor, The Rockefeller University.
Assistant Professor of Medicine, Cornell University Medical College
1979-1985 Associate
Professor and Physician, The Rockefeller University
1979-1987 Adjunct
Associate Professor of Medicine and Pharmacology, Cornell University Medical
College
1982-1987 Adjunct
Attending Physician, Department of Medicine (Gastroenterology), Memorial-Sloan
Kettering Cancer Center, New York, N.Y.
1985-1987 Professor,
Departments of Medicine and Pharmacology, and Director, Clinical Research
Center, New York Medical College, Valhalla, N.Y.
1985-1986 Medical
Director, The Institute of Clinical Pharmacology, Valhalla, N.Y.
1985-1990 Adjunct
Professor and Visiting Physician, The Rockefeller University, New York,
N.Y.
April 1987-current Professor,
Departments of Preventive Medicine and Community Health, Internal Medicine, and
Pharmacology and Toxicology; Member, Graduate Faculty; Active Member of the
Medical Staff, The University of Texas Medical Branch, Galveston, Texas.
April 1987-1990 Associate
Director, Division of Human Nutrition, The University of Texas Medical Branch,
Galveston, Texas.
September 1990-current Director, Division of Human Nutrition. The University of Texas Medical Branch,
Galveston, Texas.
December 1993-current Associate Program Director, General Clinical Research
Center, The University of Texas Medical Branch, Galveston, Texas; Acting
Program Director, 2002.
September 1998-current Director, Clinical Research Education Office, The
University of Texas Medical Branch, Galveston, Texas.
July 2000-2003 Co-Director,
Gastrointestinal/Nutrition Course, School of Medicine, The University of Texas
Medical Branch, Galveston, Texas.
RESEARCH ACTIVITIES:
A. Area of Research: Nutritional pharmacology,
including effects of diet on drug metabolism
Porphyrias and other disorders of heme metabolism in
man.
B. Grant Support: (since
1986)
|
|
|
|
|
Funding Period |
|||
|
Agency |
Title |
Direct
Costs |
Total Costs |
Start |
End |
||
|
USPHS-FDA
Orphan Drug Program |
LHRH
Analogue for Prevention of Porphyric Attacks |
$115,338
|
$170,934
|
9/30/86 |
1/31/90 |
||
|
American
Porphyria Foundation |
Porphyria
Research Fund |
$2,000 |
$2,000 |
8/1/87 |
7/31/96 |
||
|
TAP
Pharmaceuticals |
Porphyria
Research Fund |
$4,706 |
$4,706 |
8/1/87 |
7/31/96 |
||
|
American
Porphyria Foundation |
Porphyria
Research Fund |
$1,000 |
$1,000 |
8/1/87 |
7/31/96 |
||
|
Rockefeller
University |
Comparison
of the Effects of Diet and Cimetidine on Hepatic Drug Oxidation Rates in Man |
$35,000 |
$35,000 |
10/1/87 |
8/31/93 |
||
|
USPHS-FDA
Orphan Drug Program |
Erythropoietin
for Hemodialysis-Associated Porphyria |
$53,556 |
$75,097 |
1/1/89 |
12/31/91 |
||
|
R. W.
Johnson Pharmaceutical Research Institute |
Histrelin
for Prevention of Porphyria Attacks |
$24,500 |
$26,950 |
6/1/89 |
6/30/92 |
||
|
American
Porphyria Foundation |
Nutritional
Factors in Acute Intermittent Porphyria |
$1,000 |
$1,000 |
5/4/89 |
7/31/96 |
||
|
American
Porphyria Foundation |
Nutritional
Factors in Acute Intermittent Porphyria |
$5,000 |
$5,000 |
8/5/89 |
7/31/96 |
||
|
American
Porphyria Foundation |
Treatment
of Acute Porphyrias with Heme Arginate |
$5,000 |
$5,000 |
11/1/90 |
7/31/96 |
||
|
Amgen,
Inc. |
Studies
on the treatment of porphyria cutanea tarda associated with hemodialysis |
$36,364 |
$40,000 |
2/1/91 |
8/31/97 |
||
|
Metabolic
Solutions, Inc. (NIH SBIR Grant collaborative agreement) |
Effects
of Diet on Caffeine and Methacetin Breath Tests |
$6,500 |
$9,425 |
4/1/92 |
4/1/93 |
|
|
|
Intramural
Small Grant, University of Texas Medical Branch (Guion Pool Keating Cancer
Fund and the UTMB Annual Fund) |
Chloroquine
to Control Photosensitivity from Therapeutic Porphyrins |
$12,500 |
$12,500 |
4/1/92 |
3/31/93 |
|
|
Grant Support (cont'd):
|
|
|
Direct |
Total |
Funding Period |
||
|
Agency |
Title |
Costs |
Costs |
Start |
End |
|
|
American
Porphyria Foundation |
Endocrine
Manipulation for Cyclic Attacks of Porphyria |
$5,000 |
$5,000 |
8/1/92 |
4/30/94 |
|
|
USPHS-FDA
Orphan Drug Program |
Heme
Arginate for Treatment of Acute Porphyria |
$231,240 |
$339,923 |
8/1/92 |
7/31/95 |
|
|
Haskell
B. Smith |
Bequest
for Porphyria Research |
$23,284 |
$23,284 |
9/1/92 |
3/31/94 |
|
|
Amgen,
Inc. |
Studies
on the treatment of porphyria cutanea tarda associated with hemodialysis |
$44,000 |
$48,400 |
2/1/93 |
7/31/97 |
|
|
Leiras
Oy Pharmaceuticals |
Heme
Arginate for Acute Porphyria |
$225,344
|
$247,878 |
3/1/93 |
Open |
|
|
American
Porphyria Foundation |
Drug
Safety in Porphyria |
$10,000 |
$10,000 |
5/1/94 |
7/31/96 |
|
|
Pfizer,
Inc. |
An Open
Study to Compare the Safety, Toleration and Pharmacokinetics of Oral
CP-99,219 in Patients with Chronic Hepatic Insufficiency and in Healthy
Subjects |
$208,815 |
$260,525 |
5/1/94 |
7/31/97 |
|
|
USPHS-FDA
Orphan Drug Program |
Heme
Arginate for Treatment of Acute Porphyria |
$362,419 |
$541,816 |
8/1/95 |
7/31/98 |
|
|
Pfizer,
Inc. |
Phase I,
Multiple Dose Open Study Designed to Compare the Safety and Pharmacokinetics
of Ziprasidone in Subjects with Normal Hepatic Function to Subjects with
Hepatic Impairment |
$50,544 |
$67,392 |
11/7/96 |
7/31/97 |
|
|
American
Porphyria Foundation |
Telemedicine
in Porphyria |
$15,000 |
$15,000 |
1/1/97 |
Open |
|
|
DUSA
Pharmaceuticals |
A long
term study of acute intermittent porphyria |
$36,750 |
$45,973 |
7/7/97 |
9/30/98 |
|
|
USPHS-FDA
Orphan Drug Program FD-R-001459 |
Tin
Mesoporphyrin and Heme Therapy in Acute Porphyria |
$591,884 |
$887,826 |
9/30/97 |
4/30/03 |
|
|
USPHS-National
Heart Lung and Blood Institute K30
HL04126 |
Clinical
Research Education Program at UTMB |
$924,377 |
$997,699 |
6/1/99 |
5/31/05 |
|
|
American
Porphyria Foundation |
Drug
Safety in Acute Porphyria |
$10,000 |
$10,000 |
8/1/00 |
Open |
|
|
USPHS-NIH K07 HL04326-01 |
Development of a Longitudinal Nutrition Curriculum (Subcontract;
PI: Marilyn Edwards, PhD, UT Houston) |
$30,825 |
$33,291 |
4/1/00 |
3/31/02 |
|
|
USPHS-National Institute on Alcohol Abuse and Alcohol 1-RO1
AA12852 |
Alcohol-induced
cytochromes P450 in HCV/HIV oxidative injury (Subcontract; PI: Steven
Shedlofsky, MD, U KY) |
$62,250 |
$92,752 |
9/30/00 |
9/29/04 |
|
|
US Army BC004028 |
Soybean
Diet and Breast Density (PI: Lee-Jane Lu, PhD) |
$2,001,452 |
$2,983,163 |
9/1/01 |
8/31/07 |
|
|
American Institute for Cancer Research |
Comparative Hormonal Effects of Diets
Containing Soy and Animal Protein |
$149,920 |
$164,912 |
9/1/01 |
12/30/05 |
|
|
American
Porphyria Foundation |
Drug
Safety in Acute Porphyria (support for further studies) |
$15,000 |
$15,000 |
10/1/02 |
Open |
|
|
NIH 1RO1CA95545-01A1 |
Mammographic Density and Soy Isoflavones (PI:
Lee-Jane Lu, PhD) |
$631,881 |
$1,418,535 |
09/15/03 |
08/31/07 |
|
|
|
|
|
|
Funding Period |
||
|
Agency |
Title |
Direct
Costs |
Total Costs |
Start |
End |
|
|
A
multicentre, double-blind, randomized, placebo-controlled, parallel group
trial investigating the efficacy and safety to Porphozym™ (recombinant human
porphobilinogen deaminase) in the treatment of acute attacks in AIP |
$113,500 |
$14,188 |
4/23/03- |
4/26/06 |
||
|
USPHS-NIH
(funding
to UTMB through Wyle Laboratories) 1RO1GM64797 (Co-investigator;
PI: Putscha, L.) - |
Bioavailability and Pharmacodynamics of
Promethazine in Human Subjects |
~$100,000 |
~$100,000 |
8/10/02 |
11/30/05 |
|
|
USPHS-FDA
Orphan Drug Program FD-R-002604 |
Hydroxychloroquine
vs. Phlebotomy for Porphyria Cutanea Tarda |
$584,204 |
$861,049 |
9/30/05 |
9/30/08 |
|